Rayca Precision presents on the Slush Startup Stage as a Slush 100 semifinalist
Selected among the top 20 semifinalists of the Slush 100 competition, Rayca presented its approach to designing immuno-oncology and rare-disease therapeutics.
Rayca Precision was selected as one of the top 20 semifinalists of the Slush 100 competition at Slush 2025 in Helsinki, and presented on the Startup Stage.
Pouya Behrouzi, Co-founder and CEO, shared how Rayca designs next-generation immuno-oncology and rare-disease therapeutics across small molecules, peptides and antibodies, combining generative models with physics-based validation.
“Being selected as a Top 20 semifinalist in the Slush 100 competition was more than a milestone. Standing on the Startup Stage was a moment that validated the work our team has been building quietly for the past year.”
Across the week the team met investors, pharma leaders, academic partners and founders working to accelerate drug discovery, conversations that have since led to new collaborations.
